A Phase I Trial of A-CAR032 in Participants With mCRPC — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
China
Beijing Cancer Hospital, Beijing, Beijing Municipality Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Last updated January 2026